| dc.contributor.author | External author(s) only | |
| dc.date.accessioned | 2020-06-03T15:01:45Z | |
| dc.date.available | 2020-06-03T15:01:45Z | |
| dc.date.issued | 2020-04 | |
| dc.identifier.citation | Danielle Newby, Daniel Prieto-Alhambra, Talita Duarte-Salles, David Ansell, Lars Pedersen, Johan van der Lei, Mees Mosseveld, Peter Rijnbeek, Glen James, Myriam Alexander, Peter Egger, Jana Podhorna, Robert Stewart, Gayan Perera, Paul Avillach, Solène Grosdidier, Simon Lovestone & Alejo J. Nevado-Holgado Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Alz Res Therapy 12, 38 (2020) | en |
| dc.identifier.issn | 1758-9193 | |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/474 | |
| dc.description | This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data | en |
| dc.description.abstract | Background
Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.
Methods
A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia.
Results
Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52–0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17–0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57–1.37).
Conclusions
Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk. | en |
| dc.description.sponsorship | Supported by the NIHR | en |
| dc.description.uri | https://doi.org/10.1186/s13195-020-00606-5 | en |
| dc.language.iso | en | en |
| dc.subject | Dementia | en |
| dc.subject | Rheumatoid Arthritis | en |
| dc.title | Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study | en |
| dc.type | Article | en |
